Indivior director granted 3,722 RSUs

Indivior Pharmaceuticals director Keith Humphreys received an equity grant of 3,722 shares of common stock on January 26, 2026, reported as an acquisition at a price of $0 per share.

Rhea-AI Filing Summary

Indivior Pharmaceuticals director Keith Humphreys received an equity grant of 3,722 shares of common stock on January 26, 2026, reported as an acquisition at a price of $0 per share. Following this grant, he beneficially owns 9,524 shares directly.

The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to one share of common stock. The RSUs vest on the day immediately preceding the first annual stockholders’ meeting after the grant date, conditioned on his continued service as of the vesting date.

Insider Trade Summary

Grant/Award: 3,722 shares

Grant/Award 1 txn

Insider Humphreys Keith

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,722	$0.00	$0.00

Holdings After Transaction: Common Stock — 9,524 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) report for Keith Humphreys?

Indivior reported that director Keith Humphreys received 3,722 shares of common stock on January 26, 2026 via an equity grant. The transaction was recorded at $0 per share as part of his director compensation, increasing his directly held stake to 9,524 shares.

What type of equity award did Indivior (INDV) grant to Keith Humphreys?

The company granted Keith Humphreys 3,722 restricted stock units (RSUs), each representing a right to one share of Indivior common stock. These RSUs function as stock-based compensation, aligning the director’s interests with shareholders through contingent future share delivery rather than immediate cash payment.

When do Keith Humphreys’ Indivior (INDV) RSUs vest?

The RSUs granted to Keith Humphreys vest on the day immediately preceding the first annual meeting of Indivior stockholders following the grant date. Vesting is conditioned on his continued service to the company through that vesting date, tying compensation to ongoing board participation.

How many Indivior (INDV) shares does Keith Humphreys own after this Form 4?

After the reported grant, Keith Humphreys beneficially owns 9,524 shares of Indivior common stock directly. This total includes the newly acquired 3,722 shares from the RSU grant, as reflected in the Form 4’s post-transaction holdings column for non-derivative securities.

Was cash paid for the shares in Keith Humphreys’ Indivior (INDV) grant?

No cash was paid for the 3,722 shares reported, as the transaction price is shown as $0 per share. The shares arise from a restricted stock unit grant, representing stock-based compensation rather than an open-market purchase requiring cash outlay by the director.

What role does Keith Humphreys hold at Indivior (INDV)?

Keith Humphreys is identified as a director of Indivior Pharmaceuticals, Inc. on the Form 4. The reported RSU grant represents part of his compensation for board service, and his holdings are reported as directly owned, reflecting his personal beneficial ownership stake in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humphreys Keith

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		3,722(1)	A	$0	9,524	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Remarks:

	/s/ Jordan Saltzberg, Power of Attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.